34 volunteers diagnosed as chronically mentally ill were administered a questionnaire to evaluate what factors were important in preventing rehospitalization. The volunteers were divided into two groups based on their relapse history. Analysis showed the nonrelapse group were more likely to attribute factors such as in-home therapy, taking medication, and having fun with friends than did the group who had experienced at least one relapse in the past 24 months.

No abstract

Beta-lactams are a kind of antibiotics frequently used to treat infections. Many people with negative allergy tests for these betalactams are still labeled as allergic in their medical records. This research aims to estimate the actual allergy prevalence to these antibiotics. The rate between the quantity of practiced tests and the number of people who have been consequently delabeled as allergic is also to be studied. METHODS: From January to June 2019, in the HUVM Department of Allergy, 149 allergy tests were practiced (n5149) in patients ranging from 1 to 86 years old, in order to discard beta-lactams allergy. These were skin tests (with PPL, MDM, penicillin G, amoxycillin/clavulanate, cefuroxime, and the beta-lactam involved), as well as controlled exposure trials. The outcome was afterwards compared with the allergy records database in order to ponder the rate of patients who are still labeled as allergic to these antibiotics. RESULTS: The prevalence of allergic patients to beta-lactams was of 12.75%. Allergy was discarded in 84.56% of the cases. After this research, 40.47% of the latter were still labeled as allergic to beta-lactams, whereas 58.73% of them already had their medical record delabeled. CONCLUSIONS: Nearly half of the patients discarded as beta-lactams allergic are still labeled as such in their medical records. These data prove not only the convenience of practicing allergy tests on these patients, but also of delabeling their medical records according to the results obtained from the tests.

No abstract

Objective: To estimate the potential risk for a future postmarket black box warning (BBW) of US Food and Drug Administration (FDA)-approved monoclonal antibodies (mAbs) because of the importance for medical clinicians to understand mAb risks and benefits, including unknown future risks, especially for recently approved mAbs. Methods: The complete dates of the study were March 16, 2020, through May 12, 2021. We searched the FDALabel database online and reviewed the scientific literature to determine current and previous FDAapproved mAbs as of March 2020. The BBWs and initial FDA-issued safety warnings were identified. The BBWs were categorized as premarket or postmarket. For mAbs with specific postmarket BBWs, previous FDA labels were evaluated to identify the presence or absence of an initial corresponding specific FDA warning. Results: In March 2020, a total of 83 mAbs had FDA approval; 33 had BBWs (27 premarket and 13 postmarket BBWs). Of these 33 mAbs, 55 individual specific BBWs existed (36 premarket and 19 postmarket specific warnings). On average, the specific BBWs occurred in the postmarket period at a rate of 3.4% (19/562) per year. Most (73.7%; 14/19) specific postmarket BBWs were preceded by an FDA warning in a median time of 3.61 (interquartile range, 1.36-5.78) years. Specific postmarket BBWs not preceded by a specific FDA product label warning occurred at an average rate of 0.9% (5/562) per year. Conclusion: Specific postmarket BBWs occurred in FDA-approved mAbs at a rate of 3.4% per year. Specific postmarket BBWs not preceded by a specific FDA product label warning had a rate of 0.9% per year.